Clinical trials: Irritable Bowel Syndrome - Diarrhoea
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Irritable Bowel Syndrome (IBS)
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
- Trial name
- RESTORE (NCT01887002)
- Testing
- ONO-2952
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome (IBS)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- RESTORE (NCT01844180)
- Testing
- ONO-2952
- Where
- 48 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ono Pharma USA Inc
Diarrhea-predominant Irritable Bowel Syndrome
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01870895
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
Diarrhea-predominant Irritable Boewl Syndrome
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)
- Trial name
- NCT06753890
- Testing
- Changkang granules
- Where
- 30 sites in China
- Volunteers
- 520 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
This is a A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea type (IBS-D).The…
- Trial name
- NCT05923892
- Testing
- OPS-2071
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Otsuka Beijing Research Institute
Irritable Bowel Syndrome With Diarrhea
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will evaluate the effects of ORP-101 versus placebo on stool consistency and abdominal pain in patients with Irritable Bowel Syndrome with Diarrhea (IBS-D).
- Trial name
- NCT04129619
- Testing
- ORP-101
- Where
- 74 sites in United States
- Volunteers
- 321 people
- Sponsor
- OrphoMed, Inc.
Irritable Colon
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
- Trial name
- NCT00370032
- Testing
- alosetron
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days.
- Trial name
- NCT00269412
- Testing
- Rifaximin
- Where
- 67 sites in United States
- Volunteers
- 525 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome
Safety and Efficacy of a Probiotic Supplement in IBS-D
This study aims to assess the safety and efficacy of a single probiotic strain on symptom severity in adults with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- IBIS (NCT05754177)
- Testing
- Probiotic
- Where
- Slovenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Small Intestinal Bacterial Overgrowth, SIBO
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT06317441
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Nimble Science Ltd.
Irritable Bowel Syndrome
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of…
- Trial name
- NCT03339128
- Testing
- Eluxadoline
- Where
- 46 sites in United States, Bulgaria and 7 more
- Volunteers
- 272 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
- Trial name
- CDNK333B2201 (NCT00699166)
- Testing
- DNK333
- Where
- 29 sites in United States
- Volunteers
- 135 people
- Sponsor
- Novartis
Diarrhea-predominant Irritable Bowel Syndrome
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and…
- Trial name
- NCT03977155
- Testing
- BOS-589
- Where
- 58 sites in United States
- Volunteers
- 133 people
- Sponsor
- Boston Pharmaceuticals
Diarrhea Predominant Irritable Bowel Syndrome
A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
- Trial name
- NCT01896583
- Testing
- ASP7147
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seldar Pharma, Inc.
Diarrhoea Predominant Irritable Bowel Syndrome
Retrospective Study of IBS-D Patients Previously Receiving SBI
This is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken EnteraGam for management of their IBS-D for at least eight weeks.
- Trial name
- NCT02661425
- Testing
- EnteraGam
- Where
- 16 sites in United States
- Volunteers
- 165 people
- Sponsor
- Entera Health, Inc
IBS - Irritable Bowel Syndrome
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)
The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in…
- Trial name
- NCT05509725
- Testing
- Probiotic formulation
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions